ATE542534T1 - Methode zur schmerzbekämpfung - Google Patents

Methode zur schmerzbekämpfung

Info

Publication number
ATE542534T1
ATE542534T1 AT04022073T AT04022073T ATE542534T1 AT E542534 T1 ATE542534 T1 AT E542534T1 AT 04022073 T AT04022073 T AT 04022073T AT 04022073 T AT04022073 T AT 04022073T AT E542534 T1 ATE542534 T1 AT E542534T1
Authority
AT
Austria
Prior art keywords
pain control
anolgs
saxitoxin
tetrodotoxin
derivatives
Prior art date
Application number
AT04022073T
Other languages
English (en)
Inventor
Qingbin Dong
Frank Haykong Shum
Original Assignee
Wex Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wex Medical Ltd filed Critical Wex Medical Ltd
Application granted granted Critical
Publication of ATE542534T1 publication Critical patent/ATE542534T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Laser Surgery Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04022073T 2000-09-18 2001-09-11 Methode zur schmerzbekämpfung ATE542534T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB001245171A CN1284536C (zh) 2000-09-18 2000-09-18 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用

Publications (1)

Publication Number Publication Date
ATE542534T1 true ATE542534T1 (de) 2012-02-15

Family

ID=4590472

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01982091T ATE447959T1 (de) 2000-09-18 2001-09-11 Methode zur reduktion des schmerzempfindens
AT04022073T ATE542534T1 (de) 2000-09-18 2001-09-11 Methode zur schmerzbekämpfung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01982091T ATE447959T1 (de) 2000-09-18 2001-09-11 Methode zur reduktion des schmerzempfindens

Country Status (26)

Country Link
US (1) US6407088B1 (de)
EP (3) EP2298306B1 (de)
JP (1) JP2004508404A (de)
KR (2) KR100891568B1 (de)
CN (1) CN1284536C (de)
AT (2) ATE447959T1 (de)
AU (1) AU2002213785A1 (de)
BG (1) BG107690A (de)
BR (1) BR0113961A (de)
CA (1) CA2421562C (de)
DE (1) DE60140466D1 (de)
EA (1) EA004870B1 (de)
EE (1) EE200300106A (de)
ES (1) ES2435463T3 (de)
HR (1) HRP20030202A2 (de)
HU (1) HUP0302677A3 (de)
IL (1) IL154342A0 (de)
IS (1) IS6719A (de)
MX (1) MXPA03002389A (de)
NO (1) NO323960B1 (de)
PL (1) PL360616A1 (de)
SK (1) SK3732003A3 (de)
UA (1) UA76960C2 (de)
WO (1) WO2002022129A1 (de)
YU (1) YU17103A (de)
ZA (1) ZA200301852B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526648A (ja) 1997-04-22 2001-12-18 コセンシス・インコーポレイテッド 炭素環及びヘテロ環で置換されたセミカルバゾン及びチオセミカルバゾン、及びその使用
CN1236773C (zh) 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
US7119062B1 (en) 2001-02-23 2006-10-10 Neucoll, Inc. Methods and compositions for improved articular surgery using collagen
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
CN1203860C (zh) * 2001-06-22 2005-06-01 威克斯医药有限公司 钠离子通道阻断剂和阿司匹林在制备用于对哺乳动物进行协同镇痛的药物中的应用
US20030100574A1 (en) 2001-11-15 2003-05-29 Wilson Nestor Antonio Lagos Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies
WO2004013637A1 (en) * 2002-08-01 2004-02-12 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 37 (gpr37)
AU2004207010A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
JP2005154368A (ja) * 2003-11-27 2005-06-16 Teikoku Seiyaku Co Ltd ジソピラミド含有神経因性疼痛の鎮痛剤
CN1997373B (zh) * 2004-05-07 2010-12-22 菲特托克斯有限公司 藻毒素及其用途
JP2007538010A (ja) * 2004-05-07 2007-12-27 ファイトトックス リミテッド フィコトキシンの経皮投与
US20050282836A1 (en) * 2004-06-22 2005-12-22 Weiyang Lin Solid orally ingestible formulations of tetrodotoxin
US20060034823A1 (en) * 2004-08-13 2006-02-16 Paul Reid Method of production and use of crotoxin as an analgesic
CN100363006C (zh) * 2004-08-20 2008-01-23 厦门朝阳生物工程有限公司 一种戒毒制剂及其制备方法
EP1799219A1 (de) * 2004-09-21 2007-06-27 Laboratorios del Dr. Esteve S.A. Tetrodotoxin und seine derivate zur behandlung von neuropathischen schmerzen mit ursprung im zentralen nervensystem
US20100075992A1 (en) * 2004-09-22 2010-03-25 Laboratorios Del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treament of peripheral-nervously derived neuropathi pain
EP1690541A1 (de) * 2005-02-11 2006-08-16 Laboratorios Del Dr. Esteve, S.A. Verwendung eines Natriumkanalblockers und deren Analoga zur Behandlung von Nikotinabhängigkeit
TW200640463A (en) * 2005-02-11 2006-12-01 Esteve Labor Dr Use of sodium channel blockers and their analogues for the treatment of nicotine dependency
EP1714655A1 (de) * 2005-04-22 2006-10-25 Laboratorios Del Dr. Esteve, S.A. Verwendung eines Natriumkanalblockers und deren Analoga zur Behandlung von Nikotinabhängigkeit
EP1702627A1 (de) * 2005-03-18 2006-09-20 Laboratorios Del Dr. Esteve, S.A. Analgetische Kombination aus Natriumkanalblocker und Opioid Antagonisten
EP1931349A4 (de) * 2005-08-25 2009-08-05 Wex Pharmaceuticals Inc Verwendung von natriumkanalblockern zur behanldung von muskel- und skelettschmerzen
EP1928452A4 (de) * 2005-08-25 2010-09-01 Wex Medical Ltd Verwendung von natriumkanalblockern zur behanldung von viszeralen schmerzen oder schmerzen durch krebsbehandlung
US20070148159A1 (en) * 2005-12-22 2007-06-28 Reid Paul F Use of crotoxin as an analgesic - CIP
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
EP1844781A1 (de) 2006-02-22 2007-10-17 Wex Pharmaceuticals Inc. Verwendung von Natriumkanalblockern für die Behandlung von vorzeitigen Wehen
EP2394646B1 (de) 2006-03-27 2018-07-25 Wex Medical Limited Verwendung von Natriumkanalblockern zur Behandlung von neuropathischen Schmerzen infolge von Chemotherapie
WO2007110220A1 (en) * 2006-03-27 2007-10-04 Wex Pharmaceuticals Inc. USE OF 4,9-ANHYDRO-TETRODOTOXIN FOR THE TREATMENT OF DISEASES RELATED TO THE VOLTAGE-GATED SODIUM CHANNEL α SUBUNIT NAV 1.6
EP1844782A1 (de) * 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc 4,9-Anhydro-Tetrodoxin zur Behandlung von Krankheiten die in Zusammenhang mit der Potential-abhängigen Natrium-Kanal Subeinheit Nav1.6 stehen
EP1844783A1 (de) * 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc 4,9-Anhydro-Tetrodoxin zur Behandlung von Krankheiten die in Zusammenhang mit der Potential-abhängigen Natrium-Kanal Subeinheit Nav1.6 stehen
CN100438873C (zh) * 2006-06-26 2008-12-03 黄致强 将河鲀毒素作为镇痛药的耐受抑制剂在制备复方镇痛制剂中的应用
EP1882692A1 (de) * 2006-07-28 2008-01-30 Wex Pharmaceuticals Inc. Dimethano-[1,3]dioxocino[6,5-D]Pyrimidine-Spiro-Derivate von Tetrodotoxin, Verfahren ihrer Herstellung und ihre Verwendung zur Behandlung von Schmerzen
CN101730467A (zh) * 2007-07-06 2010-06-09 努恩治疗学股份有限公司 神经病性疼痛的治疗
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
US8952152B2 (en) 2009-03-24 2015-02-10 Proteus S.A. Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof
US20120034296A1 (en) * 2009-04-08 2012-02-09 Massachusetts Institute Of Technology Prolonged duration local anesthesia with minimal toxicity
US9107925B2 (en) 2010-02-10 2015-08-18 Phytotox Limited Sodium channel blocker for treatment of loss of superficial sensitivity
JP2014504184A (ja) 2010-12-01 2014-02-20 スパイナル・モデュレーション・インコーポレイテッド 神経構造への薬剤の直接送達
MX2015010749A (es) 2013-03-14 2015-11-30 Regeneron Pharma Anticuerpos humanos para nav1.7.
CN105142625B (zh) 2013-03-15 2019-09-06 儿童医学中心公司 用于长效局部麻醉的新蛤蚌毒素组合配制品
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN107198689A (zh) * 2017-07-11 2017-09-26 东新皓特（北京）生化科技有限公司 用于治疗疼痛病症的河豚毒素药物组合物及外用药

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029793A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4022899A (en) 1973-06-12 1977-05-10 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
AU1888195A (en) * 1994-03-17 1995-10-03 Nanning Maple Leaf Pharmaceutical Co. Ltd. The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence
CN1072486C (zh) * 1996-09-24 2001-10-10 王维国 用于戒毒、镇痛的药剂及其制法
AU6883798A (en) * 1997-04-02 1998-10-22 Regents Of The University Of California, The Method of anesthesia
US6326020B1 (en) * 1997-05-16 2001-12-04 Children's Medical Center Corporation Local anesthetic formulations
CN1236773C (zh) * 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用

Also Published As

Publication number Publication date
NO20030915D0 (no) 2003-02-27
KR20030034181A (ko) 2003-05-01
YU17103A (sh) 2006-03-03
AU2002213785A1 (en) 2002-03-26
KR100891568B1 (ko) 2009-04-03
IL154342A0 (en) 2003-09-17
NO20030915L (no) 2003-04-25
UA76960C2 (en) 2006-10-16
IS6719A (is) 2003-02-14
DE60140466D1 (de) 2009-12-24
EP2298306A1 (de) 2011-03-23
BG107690A (bg) 2004-01-30
HUP0302677A3 (en) 2005-01-28
CN1284536C (zh) 2006-11-15
JP2004508404A (ja) 2004-03-18
EP1563839B1 (de) 2012-01-25
NO323960B1 (no) 2007-07-23
HRP20030202A2 (en) 2005-02-28
CA2421562C (en) 2011-05-24
EP2298306B1 (de) 2013-09-11
EP1563839A1 (de) 2005-08-17
EE200300106A (et) 2005-04-15
PL360616A1 (en) 2004-09-20
HUP0302677A2 (hu) 2003-11-28
ES2435463T3 (es) 2013-12-19
SK3732003A3 (sk) 2005-05-05
EP1320369A1 (de) 2003-06-25
WO2002022129A1 (en) 2002-03-21
MXPA03002389A (es) 2004-03-12
KR20070112864A (ko) 2007-11-27
CA2421562A1 (en) 2002-03-21
ATE447959T1 (de) 2009-11-15
EA004870B1 (ru) 2004-08-26
BR0113961A (pt) 2004-01-13
EP1320369B1 (de) 2009-11-11
ZA200301852B (en) 2004-06-21
US6407088B1 (en) 2002-06-18
CN1356104A (zh) 2002-07-03
EP1320369A4 (de) 2003-07-02
EA200300172A1 (ru) 2003-12-25

Similar Documents

Publication Publication Date Title
ATE542534T1 (de) Methode zur schmerzbekämpfung
BRPI0414254A (pt) composição farmacêutica, e, métodos para fabricar uma composição farmacêutica, para o tratamento de pelo menos uma doença e para controlar a taxa de dissolução de uma formulação
EE05104B1 (et) Asetidiini derivaadid, nende valmistamise meetodid ja farmatseutiline kompositsioon
WO2005013914A8 (en) Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
GB0008269D0 (en) Combination chemotherapy
GB0112348D0 (en) Compounds
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
IL172423A0 (en) Novel formulations for opioid -based treatments of pain comprising substituted 1,4-di-piperidin-4-yl-piperazine derivatives
ATE367152T1 (de) Herstellungsverfahren für niedrig dosierte pharmazeutische zusammensetzung
BR0213449A (pt) Comprimido mastigável contendo lisina
MXPA03005980A (es) Composiciones para administracion nasal de insulina.
WO2004087700A8 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation de la douleur
MXPA03005221A (es) Composicion farmaceutica de dronedarona para administracion parenteral.
AU2001276889A1 (en) Preventing airway mucus production by administration of egf-r antagonists
WO2001008671A3 (en) Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
ATE464903T1 (de) Analgetische zusammensetzung enthaltend ein opioid und einen natriumkanalblocker
WO2001060343A3 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
WO2005082862A3 (en) Benzimidazolyl derivatives as kinase inhibitors
TWI256388B (en) Pharmaceutical combination
ITTO20000441A0 (it) Composizione terapeutica per la cura della psoriasi.
MXPA01009032A (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12.
GR1004434B (el) Χρησηατουαdiclofenacαhααποδεκτωνααλατωνααυτουαγιαατηνααντιμετωπισηατωναεγκαυματων
WO2002009668A3 (en) Pulmonary administration of flint